- Home
- CHCT vs VERV Comparison
CHCT vs VERV Comparison
Compare CHCT & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- VERV
- Stock Information
- Founded
- CHCT 2014
- VERV 2018
- Country
- CHCT United States
- VERV United States
- Employees
- CHCT N/A
- VERV N/A
- Industry
- CHCT Real Estate Investment Trusts
- VERV Medicinal Chemicals and Botanical Products
- Sector
- CHCT Real Estate
- VERV Health Care
- Exchange
- CHCT Nasdaq
- VERV Nasdaq
- Market Cap
- CHCT 422.2M
- VERV 384.2M
- IPO Year
- CHCT 2015
- VERV 2021
- Fundamental
- Price
- CHCT $16.34
- VERV $4.45
- Analyst Decision
- CHCT Buy
- VERV Strong Buy
- Analyst Count
- CHCT 4
- VERV 6
- Target Price
- CHCT $21.00
- VERV $25.75
- AVG Volume (30 Days)
- CHCT 196.0K
- VERV 2.9M
- Earning Date
- CHCT 07-29-2025
- VERV 05-14-2025
- Dividend Yield
- CHCT 11.41%
- VERV N/A
- EPS Growth
- CHCT N/A
- VERV N/A
- EPS
- CHCT N/A
- VERV N/A
- Revenue
- CHCT $116,531,000.00
- VERV $59,613,000.00
- Revenue This Year
- CHCT $7.14
- VERV $6.18
- Revenue Next Year
- CHCT $7.04
- VERV N/A
- P/E Ratio
- CHCT N/A
- VERV N/A
- Revenue Growth
- CHCT 1.33
- VERV 271.44
- 52 Week Low
- CHCT $14.76
- VERV $2.87
- 52 Week High
- CHCT $27.62
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- CHCT 48.18
- VERV 47.78
- Support Level
- CHCT $15.62
- VERV $3.89
- Resistance Level
- CHCT $16.85
- VERV $4.63
- Average True Range (ATR)
- CHCT 0.39
- VERV 0.41
- MACD
- CHCT 0.02
- VERV 0.02
- Stochastic Oscillator
- CHCT 54.96
- VERV 47.06
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.